OXPHOS is the target for Venetoclax (VEN), a potent and selective inhibitor of BCL-2, which was approved in 2018 by the FDA in combination with either DNA methyltransferase inhibitors or low-dose ARA-C for the management of older or unfit AML patients[34,35]. Here, BCL2 is linked to acute myeloid leukemia.